• Emerging company was identified as the ‘Charter Supporter” of this emerging Patient Organization, building trust and demonstrating corporate leadership in this defined patient area where they are in R&D.
  • Company has two-way dialogue with Organization leadership and patients who provide input and perspectives on a variety of corporate activities
  • Company garners insights and participation with natural history study, gaining a better understanding of the condition
  • Insights from Patient Organization and patients themselves inform the corporate strategy and identity of this emerging life sciences company as they progress through the clinical stages of drug development.